BIOABioAge Labs, Inc.
$5.69-25% 1Y
$5.69
$4.8352 weeks$25.12
The business
How BIOA's business earns
BioAge Labs, Inc. spent more than it took in: an operating loss of $121M on $8.6M of revenue, 12 months to Sep 30, 2026.
$121M
Operating loss · on $8.6M of revenue · 12 months to Sep 30, 2026
- Share count, year on year
- +28%
Share count, year on year · more shares than a year ago
Details›
- Operating margin12 months to Sep 30, 2026
- −1402%
- Net margin12 months to Sep 30, 2026
- −1254%
- Free cash flow margin
- −1198%
- R&D as % of revenue
- 1157%
- Revenue, trailing twelve months
- $8.6M
- Free cash flow, trailing twelve months
- −$103M
- Net income, trailing twelve months
- −$108M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from BIOA and who it buys from, as the companies report it.
100%of revenue comes from one customer
no supplier on file
BIOA
One customer100%
Customerswho buys
- One customer100%
Share of revenue · FY2025 10-K
Supplierswho it buys from
None disclosed.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry